Sentences with phrase «targeting leukemia»
«Prostaglandin EI inhibits leukemia stem cells: Targeting leukemia stem cells in combination with standard chemotherapy may improve treatment for chronic myeloid leukemia.»
https://www.sciencedaily.com/
«By being able to distinguish benign from malignant aging based on distinctive RNA splicing patterns, we can develop therapeutic strategies that selectively target leukemia stem cells while sparing normal hematopoietic stem cells,» she said.
More recently, Dr. Collins has been involved in development of new molecular - targeted leukemia therapies based on recent insights into leukemia biology.
«So it provides a nice way to test the ability of these compounds after being loaded into the nanoparticles to actually target leukemia stem cells within the bone marrow.»
«What is important is to be able not only t0 target leukemia cells selectively, but also to eradicate cancer stem cells as well,» Fasan says.
Not exact matches
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
In an attempt to answer this question, the researchers undertook a targeted manipulation of leukemia cell DNA in the lab.
Researchers from Instituto de Medicina Molecular (iMM) João Lobo Antunes have found a mechanism through which certain types of leukemia resist chemotherapy, thus revealing novel molecular targets that may be used to improve the efficiency of this type of treatment.
Targeting exhausted immune cells may change the prognosis for patients with acute myeloid leukemia (AML) relapse after a stem cell transplant, according to Penn State College of Medicine researchers.
Wapner's narrative follows developments from the recognition of a chromosomal abnormality in cancer cells to the production of a targeted drug against what had been a lethal leukemia.
Take ponatinib, a drug that targets the hallmark molecular abnormality in chronic myeloid leukemia (CML).
This clinical trial sponsored by Juno Therapeutics is testing JCAR017, which targets the CD19 protein expressed on most B - cell leukemias and lymphomas.
However, in some patients, the leukemia recurred without the CD19 target and expressed a protein that the CAR T cells were unable to recognize — CD22.
In PLAT - 02, the CAR T cells are reprogrammed to recognize and target the CD19 protein that is expressed by most precursor B acute lymphoblastic leukemia cells.
They will examine the safety and feasibility of administering cancer - fighting chimeric antigen receptor (CAR) T cells that have been reprogrammed to target the CD22 protein expressed by some leukemia cells.
Co-senior study investigator and cancer biologist Iannis Aifantis, PhD, says the study offers the first evidence that «drugs targeting and disrupting leukemia cells» microenvironment — or what goes on around them — could prove effective against the disease.»
Other ongoing stem cell trials are targeting blood disorders like aplastic anemia, leukemia, lymphoma, and, of course, sickle - cell disease.
The team has shown that the microenvironment that controls hematopoietic stem cells can be targeted for the treatment of a set of disorders called myeloproliferative neoplasias, the most prominent of which are chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myelogenous leukemia (CML).
During the last three years the Spanish Consortium for the Study of the Genome of the Chronic Lymphatic Leukemia, where the researchers of the present study already collaborate, has sequenced the genome of hundreds of patients with the more common leukemia in our society, identifying new mechanisms of tumor progression and new therapeutic Leukemia, where the researchers of the present study already collaborate, has sequenced the genome of hundreds of patients with the more common leukemia in our society, identifying new mechanisms of tumor progression and new therapeutic leukemia in our society, identifying new mechanisms of tumor progression and new therapeutic targets.
The effectiveness of the therapy lies in its ability to target a pro-survival cell signaling pathway known as PI3K / AKT / mTOR, upon which the leukemia cells have become dependent.
«New therapeutic target for treatment of acute myeloid leukemia discovered.»
A study by the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has found new interactions between two molecules involved in acute myeloid leukemia (AML), STAT3 and PRL - 3, which may offer a new therapeutic target for cancer treatment.
The findings are particularly noteworthy because drugs that act on the newly discovered target, a protein known as PIM1, are already in clinical trials for leukemia and multiple myeloma.
«These findings could lead to a new therapeutic strategy for patients with AML and potentially other diseases by targeting patients whose leukemia cells display activation of a specific survival pathway.»
«RNA - splicing - targeted therapies may be a potent and selective way to clear leukemia stem cells and prevent relapse.»
«Opening the door to the cause of myeloid leukemia: Finding the targets of common mutation.»
Professor Chris Bunce, Research Director at leukemia & Lymphoma Research, said: «Targeted drugs, like monoclonal antibodies, have shown great promise in recent years in effectively treating a patient's disease while minimising side effects.
The modified T cells contain a protein known as a chimeric antigen receptor (CAR), which is designed to target the CD19 protein found on the surface of B cells, including the cancerous B cells that characterize several types of leukemia and lymphoma.
The researchers were able to identify the new molecular targets by conducting a global proteomic analysis of human leukemia cells.
When tested in laboratory samples of leukemia cells and in animals with human - like leukemia, the approach caused cancer cells to die much more quickly than with conventional targeted therapies.
His group was the first to publish findings of dramatic molecular remissions in patients with chemorefractory acute lymphoblastic leukemia following treatment with autologous CD19 - targeted T cells.
This knowledge laid the foundation for the targeted cancer treatment revolution inaugurated by imatinib (Gleevec ®), which has made another blood cancer, chronic myelogenous leukemia, a controllable, chronic disease for many patients.
Its first target was the regulatory network involved in controlling the differentiation of THP - 1 cells, a line of human leukemia cells used in laboratory experiments.
The findings challenge the long - held theory that leukemia cells simply outperform healthy cells by living longer and suggest that targeting this «death factor» may be a viable way of combating the disease.
Other blood disorders that have shown significant benefit from targeted gene therapy in small trials include hemophilia (specifically, factor IX deficiency), severe beta - thalassemia (deficiency for the adult beta - globin gene) and leukemia, where the patient's immune cells were treated to enable them to recognize cancer cells and destroy them.
It's a very exciting time because of the potential advances to target cancers other than leukemia.
A CAR is a protein composed of an antibody that can bind to a known target — in our model we picked the CD19 antigen found on B cell leukemias.
The FDA granted approval to ofatumumab (ARZERRA), a targeted antibody against CD20, for patients with chronic lymphocytic leukemia (CLL) who are in complete or partial response after at least two lines of therapy.
The team's identification of a direct cooperation between these two cancer genes paves the way for targeted treatments - not only in ALL, but also in other leukemias where JAK3 / STAT5 could cooperate with HOXA9.
The targeted agent ibrutinib has shown a high response rate in both treatment - naive and previously treated, relapsed, refractory chronic lymphocytic leukemia (CLL) patients older than 65.
Martin Carroll, MD and Edward Stadtmauer, MD are leading efforts at this TCE to redefine the diagnostic and therapeutic approaches to blood cancers — including leukemia, lymphoma and myeloma — and provide more effective targeted therapies.
Locafaro G *, Andolfi G *, Russo F, Camisa B, Ciceri F, Bondanza A, Roncarolo MG *, Gregori S. HLA class I - dependent targeting of myeloid leukemia by IL -10-engineered human CD4 + Tr1 cells.
Biernacki's research focuses on developing targeted immunotherapy for pediatric acute myeloid leukemia, or AML.
The Hematologic Malignancies Translational Center of Excellence (TCE) is a multidisciplinary center that seeks to redefine the diagnostic and therapeutic approaches to blood cancers, including leukemia, lymphoma and myeloma, and provide more effective targeted therapies.
Mechanisms of Response and Resistance to CD19 - targeting Chimeric Antigen Receptors in Leukemia J. Joseph Melenhorst, PhD, University of Pennsylvania, United States
In addition to being integral to cell biology, tyrosine kinases also present targets for new anticancer therapies: One of the most highly touted, rationally designed anticancer compounds, Gleevec, inhibits an oncogenic tyrosine kinase whose aberrant activity fuels the rampant growth of cells in patients with chronic myeloid leukemia.
Enhanced phosphorylation of Nbs1, a member of DNA repair / checkpoint complex Mre11 - RAD50 - Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR / ABL - positive leukemia cells.
Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting.
The last few years have seen a tremendous level of discovery, with innovative, targeted therapies for leukemia and other blood cancers resulting in dramatic and sustained remissions.
A possible targeted therapy is found for a high - risk form of acute lymphoblastic leukemia, the most common childhood cancer.